Current Duke Appointments & Affiliations
Professor of Surgery
·
2023 - Present
Surgical Oncology,
Surgery
Interim Chief of Surgical Oncology
·
2025 - Present
Surgical Oncology,
Surgery
Vice Chair of Faculty Affairs in the Department of Surgery
·
2026 - Present
Surgery,
Clinical Science Departments
Member of the Duke Cancer Institute
·
2008 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
The effect of delays in cancer surgery due to the COVID-19 pandemic on cancer resectability and postoperative mortality in different tumor entities
Journal article Discover Oncology · December 1, 2026 Background: During the COVID-19 pandemic, prioritization of COVID-19 patients led to delays in oncological surgery, potentially impacting patient outcomes. This analysis examines the effects of surgical delays in various tumor entities on resectability and ... Full text CitePhase 1 trial of pre-operative image guided intensity modulated photon radiotherapy with simultaneously integrated boost to the high-risk margin for patients with retroperitoneal sarcoma.
Journal article Radiother Oncol · August 2026 This phase 1 trial using intensity modulated photon pre-operative radiotherapy for patients with retroperitoneal sarcoma demonstrated that the dose can be safely escalated to 63.0 Gy to a select tumor volume deemed at high risk for positive margins. Thus, ... Full text Link to item CiteConsensus Guideline for the Management of Malignant Gastrointestinal Obstruction in Patients with Peritoneal Surface Malignancies.
Journal article Ann Surg Oncol · June 2026 BACKGROUND: Malignant gastrointestinal obstruction (MGIO), a frequent complication of peritoneal surface malignancies (PSM), often portends a poor prognosis. The lack of high-quality evidence on optimal management strategies necessitated a national consens ... Full text Link to item CiteRecent Grants
Clinical Trials Umbrella - Scanned Beam
Clinical TrialPrincipal Investigator · Awarded by Massachusetts General Hospital · 2019 - 2025A Phase I Trial of Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies (TEMPO)
Clinical TrialPrincipal Investigator · Awarded by Amgen, Inc. · 2019 - 2025The DCN Passport: A Novel, Patient-Centered Approach to Improve Care for Gastric/Gastroesophageal Junction Cancer Across an Academic-Community Oncology Network
Clinical TrialPrincipal Investigator · Awarded by Eli Lilly and Company · 2020 - 2023View All Grants
Education
Duke University ·
1999
M.D.